What 100 mental-health patient groups thought of 15 pharma companies in 2018

PRESS RELEASE: 'The Corporate Reputation of Pharma, 2018 - the Perspective of Mental-Health Patient Groups' What 100 mental-health patient groups thought of 15 pharma companies in 2018 PATIENTVIEW 4TH EDITION 30 Sep at 10:30 am PRESS RELEASE: 'The Corporate Reputation of Pharma, 2018 - the Perspective of Mental-Health Patient Groups' 'The Corporate Reputation of Pharma in 2018 - the Perspective of 100 Mental-Health Patient Groups' ~ Contact: Alex Wyke ~ Tel: +44-(0)7960-855-019 ~ Email: report@patient-view.com EMBARGO: London, September 30th, 2019 6AM GMT ABOUT THIS REPORT AND SURVEY This the 4th edition of 'The Corporate Reputation of Pharma—from the Perspective of Mental-Health Patient Groups'. The 2018 results are drawn from a survey of patient groups worldwide, conducted November 2018 - February 2019. Profile of 2018's respondent mental-health patient groups: 100 respondent mental-health patient groups. 48 specialise in all types of mental health; 15 specialise in schizophrenia; 11 in ADHD; 6 in bipolar disorder; 4 in addiction; 2 in anxiety; 1 in eating disorders; and the others focus on other mental-health issues. Respondent groups are based in 34 countries, including the United States [13], Spain [11], and Italy [9]. 54% are national patient groups; 8% have an international geographic remit; the rest are regional (within one country), or local. Mental-health patient-group partnerships with industry: 46% of the mental- health patient groups have worked with one or more pharma companies. Company analyses: The following 15 pharma companies were analysed by the 100 mental-health patient groups for overall corporate reputation, and for performance at 12 individual indicators of corporate reputation: Allergan I AstraZeneca I Biogen I Boehringer Ingelheim I Bristol-Myers Squibb I Eli Lilly I GSK I Janssen I Lundbeck I Otsuka I Pfizer I Roche/Genentech I Sanofi I Takeda/Shire I and Teva. KEY FINDINGS ACROSS THE PHARMA INDUSTRY Percentage of respondent mental-health patient groups stating that the corporate reputation of the pharmaceutical industry as a whole was “Excellent” or “Good”, 2015-2018 The attitudes of mental-health patient groups towards the pharmaceutical industry have fluctuated over the four years that PatientView has been analysing their viewpoints; but, overall, mental-health patient groups are becoming less positive about the industry’s corporate reputation. In 2015, 38% of respondent mental-health patient groups stated that the industry had an “Excellent” or “Good” corporate reputation; in 2018, the equivalent figure was down to just 24%. Much appears to hinge on the pharma industry’s R&D output in the therapy area. 2015’s respondent mental-health patient groups were far more confident than those of 2018 that pharma had the ability to innovate, and to produce high-quality products of value to people with a mental-health condition. As many as 67% of the 2015 respondents thought pharma “Excellent” or “Good” at innovation, and 73% said the same for pharma’s ability to provide high-quality products. In 2018, those figures had fallen to 27% and 39% respectively. These negative views on pharma R&D dominate mental-health patient groups’ thinking about the pharmaceutical industry today. Yet, despite the generally gloomy opinions, a small number of 2018’s respondent mental-health patient groups did comment very favourably on recent initiatives taken by some pharmaceutical companies to deliver both new products, and new approaches, in the therapy area. Percentage of respondent patient groups stating each year that the pharmaceutical industry was “Excellent” or “Good” at two activities of importance to these patient groups: innovation and the provision of high-quality products; mental health v. all therapy areas HOW DID COMPANIES PERFORM? Despite being recognised by respondent mental-health patient groups, not all of the 15 companies included in this analysis have significant levels of engagement with these patient groups. The companies that do are: Eli Lilly; Janssen; Lundbeck; and Otsuka. Several years ago, many more companies used to work with mental-health patient groups. Back in 2015, PatientView’s survey reported active engagement by the following eight additional companies: AbbVie; Boehringer Ingelheim; Bristol-Myers Squibb; GSK; Merck & Co/MSD; Pfizer; Roche/Genentech; and Sanofi. As the PharmaTimes remarked in a May 2019 article on the pharmaceutical-industry’s involvement in mental health: “There has been a shift away from developing new drugs for mental-health disorders, despite the massive health burden they create, and the fact that they are potentially growing even more prominent.”[http://www.pharmatimes.com/web_exclusives/big_pharma_-_come_back_to_mental_health_and_invest_in_europe_1287736] Mental-health patient groups' familiarity, and partnerships, with pharma companies, 2018. Number of respondent mental-health patient groups. * Includes ‘worked with’ HOW CORPORATE REPUTATION IS MEASURED The overall corporate reputation of each company is assessed according to that company's performance (as judged by mental-health patient groups) at 12 individual indicators of corporate reputation. The RANKINGS of 15 companies for corporate reputation—from the perspective of mental-health patient groups familiar with the company, 2018 v. 2017 The indicators [listed below] have been developed over the years by PatientView, drawing on recommendations from patient groups, health professionals, health regulators, and industry. PatientView's 12 indicators used to assess pharma corporate reputation 1. Patient centricity. 2. Patient information. 3. Patient safety. 4. High-quality products. 5i. Transparency: pricing. 5ii. Transparency: clinical-trial data. 5iii. Transparency: funding of stakeholders. 6. Integrity. 7. Relationships with patient groups. 8. Providing services ‘beyond the pill’. 9i. Engaging patients in research. 9ii. Engaging patients in development. Otsuka dominated the mental-health Corporate-Reputation league tables for 2018, coming overall 1st out of 15 companies (according to the 26 respondent mental-health patient groups familiar with Otsuka). This is the first time that Otsuka has topped the Corporate-Reputation rankings in the four years that PatientView has been analysing the opinions of mental-health patient groups. Otsuka was also ranked overall 1st in 2018 by its 14 respondent mental-health patient-group partners. Janssen was ranked overall 2nd out of 15 companies for corporate reputation in 2018 (a drop of one place in the rankings, compared with 2017) by the 71 respondent mental-health patient groups claiming familiarity with Janssen. And ... Lundbeck was ranked overall 3rd out of 15 companies for corporate reputation in 2018 (the same position as in 2017) by the 43 respondent mental-health patient groups claiming familiarity with Lundbeck. -END OF PRESS RELEASE- For further information on the 2018 MENTAL-HEALTH report, please use contact details at the top of this press release PatientView Tel: ++44-(0)1547-520-965 E-mail: report@patient-view.com www.patient-view.com Registered in England Number: 3944382 Registered office: One Fleet Place, London, EC4M 7WS, UK